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Prion Diseases
Prion diseases, or transmissible spongiform encephalopathies
(TSEs), occur naturally in several species, including humans,
cattle, sheep, and deer, and can be transmitted experimentally to
many others. Typically, incubation times are relatively long,
extending to 40 years or more in humans; however, after
appearance of clinical symptoms, death mostly ensues within less
than a year, as a consequence of neurodegeneration accompanied
by accumulation of abnormal conformers of the host protein PrP.
Natural transmission usually occurs perorally, as exemplified by
the kuru epidemic among the Fore people of Papua New Guinea,
attributed to cannibalistic practices; the bovine spongiform
encephalopathy (BSE) epizootic in the United Kingdom at the
end of last century, caused by feeding of contaminated meat-and-
bone meal to cattle; or the current epizootic of chronic wasting
disease afflicting cervids in 19 states of the United States.
Transmission of BSE prions to young humans gave rise to a
limited outbreak of a novel illness, variant Creutzfeldt-Jakob
disease (vCJD), almost exclusively in the UK. Sporadic cases of
prion disease occur at very low frequency in human populations
(sCJD) and in cattle herds (atypical BSE), and are attributed to
spontaneous generation of prions in the affected individuals.
Finally, familial forms of human prion disease are linked to a
variety of different, dominant mutations in the PRNP gene, and
while afflicted families are rare, penetrance is very high.
Replication of Prions
Prions consist mainly, if not solely, of PrP
Sc (scrapie prion
protein), aggregated conformers of the GPI-linked host glycopro-
tein PrP
C (cellular prion protein). PrP
Sc propagates by converting
PrP
C to a replica of itself (Figure 1A). PrP
C may exist as an
equilibrium mixture of conformers, some of which can accrete to
PrP
Sc ‘‘seeds’’ at a critical rate [1,2]. This seeding model is
supported by the protein misfolding cyclic amplification (PMCA)
reaction, in which brain homogenate, as a source of PrP
C, is spiked
with a seed of infected brain homogenate and subjected to
multiple cycles of sonication and incubation, ultimately yielding a
vast excess of infectious prions [3]. Infectious prions arose
spontaneously in PMCA-mediated, cell-free reactions from
defined components [4], in particular from recombinant PrP, a
phospholipid, and poly(A) or poly(dT) [5], definitively laying to
rest the perennial proposal that the infectious agent is a virus-like
entity [6]. Prion-like, seeded conversion into an aggregated state
has been proposed for several mammalian proteins such as Abeta,
a-synuclein, or serum amyloid, which underlie protein misfolding
diseases, and for several fungal, in particular yeast, proteins.
Prion Strains
Prion populations may present as distinct strains: these differ in
their phenotypic properties but are associated with PrP
Sc having
the same amino acid sequence. Murine prion strains, originally
characterized by the incubation time and the neuropathology they
elicit, can be propagated indefinitely in mice homozygous for the
PrP gene. Many ‘‘classical’’ strains currently propagated in mice
and hamsters, such as 79A, 22L, and ME7, originated from
scrapie-infected sheep or goats [7] and were cloned by endpoint
dilution in mice.
Strain-specific properties of the prion are believed to be
enciphered in the conformation of the cognate PrP
Sc [8], and
indeed, distinct strains are often associated with PrP
Sc species
differing in physicochemical properties. Experiments with yeast
prion strains have shown that specific conformations can be
propagated in vitro by pure, unglycosylated proteins [9].
Nonetheless, in view of the vast multiplicity of mammalian prion
strains and their tropism for particular cell lines, it is conceivable
that post translational modifications of PrP, such as glycosylation
or association with some cellular components, might favor certain
PrP conformations and hence account for cell-specific preferential
propagation of particular strains.
The Species Barrier
In general, there is a considerable barrier to transmission of
prions between animal species, in that even massive intracerebral
trans-species inoculation causes disease at only low frequency (low
‘‘attack rate’’) and/or only after very long incubation times, if at
all. This barrier was abolished in some instances by replacing the
PrP gene of the recipient by its counterpart from the donor, but
clearly factors other than mismatch of PrP sequences contribute to
the incompatibility. Importantly, when prions are serially
transmitted from the initial trans-species recipients to further
animals of the same species, attack rates increase and incubation
times decrease, reflecting ‘‘adaptation’’ to the new host [10].
‘‘Adaptation’’ implies as a first step accretion of PrP
C from the
recipient host to the incoming PrP
Sc seed, which may be a very
inefficient process if the amino acid sequence of the host PrP
entrains a spectrum of conformations that are poorly compatible
with that of the seed. Efficient propagation may only be enabled
when the conformation of the seed changes, perhaps initially at the
‘‘growing end’’ [11], resulting in a ‘‘mutation’’ at the conforma-
tional level. Subsequently, prions may evolve to replicate more
rapidly in the new host, accounting for the striking reduction of
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the new species.
In some instances, transfer of a prion strain from one species to
another, followed by several passages in the original host species,
led to emergence of mutant strains. For example, when cloned
murine 139A prions were passaged through hamster and
subsequently passaged repeatedly in mouse a new strain, 139A-
H2M, was recovered; however, ME7 subjected to the same
procedure remained apparently unchanged [12].
Evolution of Prions
The finding that many murine prion strains replicated efficiently
in selected murine cell lines created important new experimental
opportunities. In particular, the slow, expensive, and imprecise
mouse-based bioassay for murine prions could be replaced by a
humane, rapid, and precise cell-based procedure, the standard
scrapie cell assay (SSCA) [13]. The differential susceptibility of cell
lines to various prion strains provided the basis of the cell panel
assay (CPA), which rapidly differentiates between various prion
strains on the basis of their cell tropism and their susceptibility to
various drugs, such as swainsonine or kifunensine [14,15].
The CPA revealed that serial propagation of brain-derived 22L
prions in PK1 cells led to progressive change in their properties;
while initially able to propagate in R33 cells (‘‘R33 competent’’) or
in PK1 cells in the presence of swainsonine (‘‘swainsonine
resistant’’), the prions gradually became completely R33 incom-
petent and swainsonine-sensitive (Figure 1B). When these ‘‘cell-
adapted’’ prions were returned to mouse brain, they gradually re-
acquired their former properties and became indistinguishable
from the original 22L strain [16]. Along similar lines, when
swainsonine-sensitive prions were propagated in PK1 cells in the
presence of the drug, a swainsonine-resistant prion population
emerged after a few passages, documenting adaptation to the new
environment. After withdrawal of the drug, further propagation
for several splits again yielded drug-sensitive prions [16]. These
findings suggested that prion populations constitute so-called
quasispecies [17], that is, they are composed of a variety of
conformational variants, each present at a low level; when the
environment changes, the most efficiently replicating variant
becomes the predominant component of the population, which
then constitutes a distinct sub-strain [1,16,18]. Indeed, PK1 cell-
adapted 22L populations were found to contain about 0.5%
swainsonine-resistant variants before ever being exposed to the
Figure 1. Propagation, mutation, and selection of prions in cultured cells. (A) The seeding model of prion propagation predicates that PrP
C
monomers add to the termini of PrP
Sc fibrils and in doing so, adopt the conformation of the constituent PrPSc subunits. (B) Prion populations are
thought to constitute quasi-species, consisting of a major species and numerous variants at low levels. Brain-adapted 22L prions are resistant to
swainsonine treatment when assayed on PK1 cells and are able to infect R33 cells (R33 competent). When propagated in PK1 cells, swainsonine-
sensitive, R33-incompetent prions gradually (passages P0 to P12) become the major species in the population because they multiply faster. (C) PK1
cell-adapted 22L prions (a) were cloned (b) in PK1 cells. The populations become heterogeneous as mutations arise during propagation (c–e). The red
circles represent swainsonine-resistant prions; when challenged with the drug, some populations (top and middle row) acquire the capacity to
become resistant while others (bottom row) do not. Schematic representation of data from reference [16].
doi:10.1371/journal.ppat.1002582.g001
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been cloned by endpoint dilution years earlier, heterogeneity must
have arisen by a mutation-like process in the interim. Mutations in
the case of prions represent conformational changes and not
modifications at the level of the protein sequence, because PrP is
encoded by the host genome and the mutation is inherent to the
proteinaceous particle. To verify whether heterogeneity of prion
populations came about by mutation, swainsonine-sensitive prions
were cloned by endpoint dilution into PK1 cells, and the infected
cells were propagated serially for up to 100 doublings and
challenged with swainsonine to determine at which stage the prion
populations acquired the capacity for becoming resistant to the
drug. Early after cloning the populations were incapable of doing
so, but most clones developed this capability after 31–86 doublings
(Figure 1C). However, at least one of nine populations failed to do
so even after 116 doublings, suggesting that the prions were
heterogeneous in regard to their ability to develop swainsonine
resistance [11,16]. Acquisition of drug resistance by murine prions
has also been reported by Ghaemmaghami et al. [19] and by yeast
prions by Shorter [20]. Most if not all of the prion variants, or sub-
strains, described above were reversible, suggesting that the
underlying conformations were readily interconvertible. In
contrast, strains are very stable, at least as long as they are
propagated in the same species. As shown in Figure 2, this suggests
a low activation energy barrier between sub-strains, readily
surmountable under physiological conditions, while high activa-
tion energy barriers prevent conversion between strains.
Concluding Thoughts
The finding that prions can acquire resistance to drugs has
significant implications for drug design. Drugs targeted to PrP
Sc
may have to be administered in combination, as in the case of
viruses, in particular HIV. Alternatively, drugs could be targeted
to bind and stabilize PrP
C or, in view of the finding that ablation of
PrP
C, at least in animals, is not detrimental to health [21,22], to
suppress its synthesis. At present no therapeutically useful drugs
are available, but deepening insight into the molecular biology of
prions may pave the way to novel approaches.
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